Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
The life of some children with hematological malignancies can be saved by the cord blood of their newborn siblings. Parents may chose to have another child in the hope of conceiving an HLA-identical donor sibling. However, there is only 25% …more
Learn more about HLA Genotyping Are you interested in Next Generation HLA Typing? Join us online for a presentation on Holotype HLA™ – HLA Genotyping Assay and Software for NGS data. Date: Thursday, 18th of September, 2014 Time: 12:00–1pm EST …more